I think PNV has already started to push through price increases on their product. Given our very low pricing relative to competitors - we have a lot of headroom to do so. Given one of the largest competitors, Integra has issues with their production - there is even more scope to push through price increase given the lack of viable alternatives.
What will further help support PNV's growth trajectory is U.S PMA approval that is expected to be gained following the end of the BARDA trial. PMA approved medical devices are often eligible for higher reimbursement rates from insurers. This will not only drive increased confidence for adoption, but also support PNV's ability to push through significant price increases.
I expect strong growth to continue, driven by both the acquisition of new customers, as well as the ability of PNV to push through price increases.
PNV Price at posting:
$2.07 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)